Patents Examined by Michael G. Hartley
  • Patent number: 10292966
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: May 21, 2019
    Assignee: Wyeth LLC
    Inventors: Eric J. Benjamin, Wendy A. Dulin, Yanning Lin, Kai Zhuang
  • Patent number: 10293063
    Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: May 21, 2019
    Assignee: Merit Medical Systems, Inc.
    Inventor: Philippe Reb
  • Patent number: 10293074
    Abstract: A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: May 21, 2019
    Assignee: KCI USA, Inc.
    Inventor: Lorraine Nisbet
  • Patent number: 10286089
    Abstract: A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: May 14, 2019
    Assignee: Duke University
    Inventor: Christopher David Lascola
  • Patent number: 10286090
    Abstract: Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes a hydrazide functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent. The portion that is not bound to a metal ion localizes the contrast agent to necrotic tissue in the subject.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: May 14, 2019
    Assignee: RF Therapeutics Inc.
    Inventors: Zhang Jidong, Curry Ken
  • Patent number: 10286088
    Abstract: Disclosed is a method of non-invasive infrared imaging, comprising (a) administering a composition containing infrared-emitting particles which contain rare earth elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles; and (b) irradiating with infrared radiation, where both excitation and emission spectra of the encapsulated particles are in the infrared region. Analogous methods of image-guided biomedical intervention, and drug tracking and delivery are also disclosed. Also disclosed is a composition for biomedical applications, containing infrared-emitting particles which contain rare earth-elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: May 14, 2019
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Dominik J. Naczynski, Mei-Chee Tan, Richard E. Riman, Charles Roth, Prabhas V. Moghe
  • Patent number: 10287292
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 14, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Patent number: 10279053
    Abstract: A method of forming a plurality of microbubbles, wherein the method disposes in a sealed container comprising a first volume at ambient pressure, a second volume of a mixture comprising one or more microbubble stabilizing materials. The first volume is greater than said second volume. The method further comprises sealing said container, introducing a gas into said sealed container, and shaking the container to form said plurality of microbubbles.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: May 7, 2019
    Assignee: NuvOx Pharma LLC
    Inventors: Evan C. Unger, Patrick W. Hendon
  • Patent number: 10280307
    Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: May 7, 2019
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
  • Patent number: 10279054
    Abstract: A method for producing a solution including a positron emitting zinc cation of 63Zn, and the method comprises bombarding a solution target including 63Cu with high energy protons to produce a solution including a positron emitting zinc cation. A method for detecting or ruling out Alzheimer's disease in a patient comprises administering to a patient a detectable amount of a compound including a positron emitting zinc cation, wherein the zinc cation is targeted to beta-amyloid in the patient, and acquiring an image to detect the presence or absence of beta-amyloid in the patient.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: May 7, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Timothy R. Degrado, Mukesh K. Pandey, Hendrik Petrus Engelbrecht, Val J. Lowe
  • Patent number: 10264976
    Abstract: Flavonoid compounds may be prepared that are selective for certain cell organelles, and may be used as biological imaging agents. Organelles that may be imaged with flavonoid compounds include mitochondria and lysosomes. Advantageously, the flavonoids show specificity to certain organelles and may exhibit a florescence “turn-on” mechanism, where the flavonoids that have target an organelle exhibit a florescence response when excited.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: April 23, 2019
    Assignee: The University of Akron
    Inventors: Yi Pang, Bin Liu
  • Patent number: 10266506
    Abstract: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 23, 2019
    Assignee: PIRAMAL IMAGING SA
    Inventors: Lutz Lehmann, Andrea Thiele, Tobias Heinrich, Thomas Brumby, Christer Halldin, Balazs Gulyas, Sangram Nag
  • Patent number: 10265418
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: April 23, 2019
    Assignee: TRANSLATUM MEDICUS INC.
    Inventor: Shelley Romayne Boyd
  • Patent number: 10265398
    Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 23, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tomé
  • Patent number: 10265421
    Abstract: The invention relates to a method of Magnetic Resonance (MR) detection, in particular 13C-MR detection, by using a diagnostic medium comprising a hyperpolarized ester, in particular ethyl acetoacetate. The method comprises the detection of the MR signal of a hyperpolarized 13C carboxylic ester and of its respective hyperpolarized metabolite.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: April 23, 2019
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Pernille Rose Jensen, Lerche H. Mathilde, Magnus Karlsson, Claudia Cabella, Sonia Colombo Serra, Luigi Miragoli, Luca Venturi, Fabio Tedoldi
  • Patent number: 10259781
    Abstract: Provided herein is technology relating to imaging agents and particularly, but not exclusively, to methods of manufacturing fluorine-18-labeled phenethylguanidines and uses thereof.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 16, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: David M. Raffel, Yong-Woon Jung, Keun-Sam Jang
  • Patent number: 10258563
    Abstract: The present invention includes a construct that comprises at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention also includes a pharmaceutical composition comprising a construct comprising at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention further includes a method of imaging a tissue or organ in a subject, a method of delivering a therapeutic cargo to a tissue or organ in a subject, and a method of treating a disease or disorder in a subject.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: April 16, 2019
    Assignee: Drexel University
    Inventors: Steven P. Wrenn, Stephen Dicker
  • Patent number: 10258701
    Abstract: Disclosed is a compound of formula (I): wherein L, R1-R5, A, B, M, and n are as defined in the specification, as well as a method of preparing the compound. Also disclosed are a method of blood-pool imaging in a mammal and a method of imaging a lymph node in a mammal, comprising use of the compound.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 16, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Xiaoyuan Chen, Lixin Lang, Gang Niu
  • Patent number: 10251592
    Abstract: Systems and methods for noninvasively determining the function capacity of the kidney are provided. In the methods, first contrast agent is injected into the vasculature of a subject. The contrast agent is to be bound with functioning glomeruli of the kidney of the subject. Then, the kidney is imaged with a magnetic resonance imaging (MRI) system to acquire MRI images of the kidney. In the images, signal magnitudes or phases of voxels of regions bound with the contrast agent are different from signal magnitudes or phases of voxels of regions not bound with the contrast agent. Afterwards, the function capacity of the kidney is determined using the MRI images. Lastly, a report of the function capacity of the kidney is generated.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: April 9, 2019
    Assignee: Nephrodiagnostics LLC
    Inventors: Kevin Michael Bennett, Scott Charles Beeman
  • Patent number: 10251960
    Abstract: The present invention discloses a solid lipid nanoparticle (SLN) comprising: a) a solid lipid core comprising at least a glyceride and/or at least a fatty acid; b) a mixture of amphiphilic components forming a shell around said core a); c) an alkaline-earth complex with a compound of formula I and/or II: d) at least a fluorescent dye selected from: a cyanine fluorescent dye and/or a polyetherocyclic compound selected from: coumarin, pyrano, quinoline, pyranoquinoline, indole and pyranoindole derivates in acid form or a pharmaceutically acceptable salt thereof. These nanoparticles allow a prolonged blood circulation half-life, show enhanced photostability and improved fluorescence signal. The dye is preserved from degradation and improves the fluorescent quantum yield.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: April 9, 2019
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Simona Ghiani, Alessandro Maiocchi, Lara Caminiti, Luigi Miragoli